NFE2L2 and cancer: Despite, the lack of specific and selective NRF2 inhibitors still represents a significant limitation to the use of alternative strategies of NRF2 inhibition, it is clear that the appropriate understanding of the clinical context, wherein these agents are supposed to exert the most beneficial effects, will pave the way to novel and tailored anti-cancer therapies.